FABRICATION, CHARACTERIZATION, AND IN VITRO EVALUATION OF PEGYLATED GLYCERIDE LABRASOL® NANOSTRUCTURED LIPID CARRIER COMPOSITES OF METHOTREXATE: THE PATHWAY TO EFFECTIVE CANCER THERAPY

RADHARANI PANDA; KETOUSETUO KUOTSU

doi:10.22159/ajpcr.2019.v12i6.33377

Authors

RADHARANI PANDA Department of Pharmaceutical Technology, Division of Pharmaceutics, Jadavpur University, Kolkata, West Bengal, India.
KETOUSETUO KUOTSU Department of Pharmaceutical Technology, Division of Pharmaceutics, Jadavpur University, Kolkata, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i6.33377

Keywords:

Methotrexate, Nanostructured lipid carrier,, Polyethylene glycolylated glyceride,, In vitro release,, MCF-7 cells,, Half maximal inhibitory concentration value,, Cellular uptake

Abstract

Objective: The objective of the current study is to optimize and evaluate the potential of polyethylene glycolylated (PEG) glyceride Labrasol® nanostructured lipid carrier (NLC) composites of methotrexate (MTX) to achieve enhanced sustained release delivery in cancer treatment.

Materials and Methods: MTX-NLC was successfully prepared by hot melt emulsification and probe sonication method for spatial and controlled release of this therapeutic agent.

Results: The solubility screening of MTX and lipids resulted in the selection of Monostearin as solid lipid, PEGylated glyceride Labrasol® and olive oil as liquid lipids for the formulation of MTX-loaded NLC composites. Particle size, zeta potential, and polydispersity index of both the composites were confirmed using dynamic light scattering, whereby Labrasol® MTX-NLC showed high entrapment efficiency and drug loading. A spherical particle shape with smooth surface of all the composites was confirmed from the scanning electron microscope and transmission electron microscopy analysis. Labrasol® MTX-NLC showed remarkably increased cytotoxic response, augmented cellular uptake, and low half maximal inhibitory concentration value in MCF-7 cells. In vitro release study confirmed that encapsulation of MTX in PEGylated glyceride Labrasol® MTX-NLC resulted in enhanced sustained release of MTX for a period of 48 h.

Conclusion: The present study establishes that PEGylated glyceride Labrasol® MTX-NLC can be considered as a promising anticancer delivery system, thereby improving antitumor efficacy of the drug.

Downloads

Download data is not yet available.

Author Biography

RADHARANI PANDA, Department of Pharmaceutical Technology, Division of Pharmaceutics, Jadavpur University, Kolkata, West Bengal, India.

Research Scholar,

Division of Pharmaceutics,

Department of Pharmaceutical Technology,

Jadavpur University,

Kolkata-700032, West Bengal, India.

References

Boyle P, Levin B. World Cancer Report. International Agency for Research on Cancer. Geneva: Distrib by WHO Press Lyon; 2008.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.

Raut I, Doijad R, Mohite S. Solid lipid nanoparticles: A promising drug delivery system. Int J Pharm Sci Res 2018;9:862-71.

Branco MT, Buttros DA, Carvalho-Pessoa E, Sobreira ML, Schincariol CN, Nahas-Neto J, et al. Atherosclerotic disease and cardiovascular risk factors in postmenopausal breast cancer survivors: A case-control study. Climacteric 2019;22:202-7.

Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 2013;71:1115-30.

Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, et al. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25 Suppl 2:12-8.

Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev 2013;65:104-20.

Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev 2015;115:10938-66.

Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res 2016;33:2373-87.

Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC, et al. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-9.

Parveen S, Misra R, Sahoo SK. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8:147-66.

Stirling DA. Nanotechnology applications. the nanotechnology revolution. Pan Stanford 2018;17:281-434.

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014;66:2-5.

Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J Control Release 2015;200:138-57.

Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991;8:47-54.

Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-8.

Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K, et al. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release 2014;190:607-23.

Esposito E, Boschi A, Ravani L, Cortesi R, Drechsler M, Mariani P, et al. Biodistribution of nanostructured lipid carriers: A tomographic study. Eur J Pharm Biopharm 2015;89:145-56.

Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol 2014;5:159.

Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 2016;12:143-61.

Thang LQ, Hanh ND, Duong DQ. Study on cause-effect relations and optimization of exemestane-loaded nanostructured lipid carriers. Int J Pharm Pharm Sci 2017;9:68-4.

Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 2013;19:29-43.

Nabi B, Rehman S, Baboota S, Ali J. Insights on oral drug delivery of lipid nanocarriers: A Win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech 2019;20:60.

Abousamra MM, Mohsen AM. Solid lipid nanoparticles and nanostructured lipid carriers of tolnaftate: Design, optimization and in vitro evaluation. Int J Pharm Pharm Sci 2015;8:380-5.

Zhao X, Tang D, Yang T, Wang C. Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system. Colloids Surf B Biointerfaces 2018;170:355-63.

Grossen P, Witzigmann D, Sieber S, Huwyler J. PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application. J Control Release 2017;260:46-60.

Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO, et al. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 2014;15:1509-15.

Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30.

Rabanel JM, Hildgen P, Banquy X. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation. J Control Release 2014;185:71-87.

Soleimanian Y, Goli SA, Varshosaz J, Sahafi SM. Formulation and characterization of novel nanostructured lipid carriers made from beeswax, propolis wax and pomegranate seed oil. Food Chem 2018;244:83-92.

Kalhapure RS, Sonawane SJ, Sikwal DR, Jadhav M, Rambharose S, Mocktar C, et al. Solid lipid nanoparticles of clotrimazole silver complex: An efficient nano antibacterial against Staphylococcus aureus and MRSA. Colloids Surf B Biointerfaces 2015;136:651-8.

Dey NS, Mukherjee B, Maji R, Satapathy BS. Development of linker-conjugated nanosize lipid vesicles: A strategy for cell selective treatment in breast cancer. Curr Cancer Drug Targets 2016;16:357-72.

Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development and in vitro/in vivo evaluation of controlled release provesicles of a nateglinide-maltodextrin complex. Acta Pharm Sin B 2014;4:408-16.

Banerjee P, Geng T, Mahanty A, Li T, Zong L, Wang B, et al. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors. Int J Pharm 2019;557:374-89.

Garg NK, Singh B, Sharma G, Kushwah V, Tyagi RK, Jain S, et al. Development and characterization of single step self-assembled lipid polymer hybrid nanoparticles for effective delivery of methotrexate. RSC Adv 2015;5:62989-99.

Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J, et al. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012;20:813-30.

Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003;257:153-60.

Bolla PK, Kalhapure RS, Rodriguez VA, Ramos DV, Dahl A, Renukuntla J. Preparation of solid lipid nanoparticles of furosemide-silver complex and evaluation of antibacterial activity. J Drug Deliv Sci Technol 2019;49:6-13.

Yogasundaram H, Bahniuk MS, Singh HD, Aliabadi HM, Uludaǧ H, Unsworth LD. BSA nanoparticles for siRNA delivery: Coating effects on nanoparticle properties, plasma protein adsorption, and in vitro siRNA delivery. Int J Biomater 2012;2012.

Avachat AM, Parpani SS. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces 2015;126:87-97.

Garg NK, Tyagi RK, Singh B, Sharma G, Nirbhavane P, Kushwah V, et al. Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-κB and FOXO1. Int J Pharm 2016;499:301-20.

Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 2010;40:325-34.

Cooley M, Sarode A, Hoore M, Fedosov DA, Mitragotri S, Gupta AS. Influence of particle size and shape on their margination and wall- adhesion: Implications in drug delivery vehicle design across nano-to-micro scale. Nanoscale 2018;10:15350-64.

Han Y, Zhang Y, Li D, Chen Y, Sun J, Kong F, et al. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine 2014;9:4107 16.

Safwat S, Ishak RAH, Hathout RM, Mortada ND. Nanostructured lipid carriers loaded with simvastatin: Effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity. Drug Dev Ind Pharm 2017;43:1112-25.

Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005;45:167-73.

Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. J Control Release 2013;172:1126-41.

Zheng D, Dai W, Zhang D, Duan C, Jia L, Liu Y, et al. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Drug Deliv 2012;19:286-91.

Liu Y, Gao D, Zhang X, Liu Z, Dai K, Ji B, et al. Antitumor drug effect of betulinic acid mediated by polyethylene glycol modified liposomes. Mater Sci Eng C Mater Biol Appl 2016;64:124-32.

Garg NK, Singh B, Jain A, Nirbhavane P, Sharma R, Tyagi RK, et al. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics. Colloids Surf B Biointerfaces 2016;146:114-26.

Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010;141:183-92.